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Two recent genome-wide association studies have described associations of SNP variants in 
PNPLA3 with nonalcoholic fatty liver and plasma liver enzyme levels in population based 
cohorts. We investigated the contributions of these variants to clinical outcomes in Mestizo 
subjects with a history of excessive alcohol consumption. We show that non-synonymous variant 
rs738409[G] (I148M) in PNPLA3 is strongly associated with alcoholic liver disease and 
progression to alcoholic cirrhosis (unadjusted OR = 2.25, P = 1.7×10−10; ancestry-adjusted OR = 
1.79, P = 1.9×10−5).  
Liver cirrhosis is the twelfth leading cause of death in the United States, with a total of 
28,175 deaths reported in 20051. Nearly half of these were classified as alcohol-related, yet this 
cause may be substantially under-reported2. Hispanics are disproportionately impacted by 
chronic liver disease3. In 2007, cirrhosis was the fourth leading cause of death in Mexico, and the 
second leading cause in adults age 15 to 64 (http://sinais.salud.gob.mx/mortalidad/). Only 10% to 
15% of alcoholics develop cirrhosis, and while patterns of alcohol consumption are clearly 
important, they do not appear to fully account for the ethnic differences in incidence rates4. 
Recently, Romeo et al.5 carried out a genome-wide association study of non-synonymous 
sequence variations in a population comprising Hispanics, African Americans and European 
Americans to identify genetic variants contributing to nonalcoholic fatty liver disease (NAFLD). 
They found strong evidence of association of an allele in PNPLA3 (rs738409[G], I148M) with 
increased hepatic fat levels (P = 5.9×10−10) and the association remained highly significant after 
adjustment for body mass index, diabetes status, ethanol use and genetic ancestry. The study also 
revealed a significant elevation in serum concentrations of alanine aminotransferase (ALT) in 
association with the rs738409[G] allele in Hispanics (P = 1.3×10−5). Resequencing the region 
revealed another allele (rs6006460[T], S453I) that was independently associated with lower 
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hepatic fat content in African Americans, the group at lowest risk of NAFLD. An independent 
genome-wide study6 aiming to find genes influencing plasma levels of liver enzymes also 
showed evidence that variants in PNPLA3 were associated with plasma levels of alanine-
aminotransferase (ALT). This study gave additional support to the hypothesis that rs738409[G] 
may confer increased susceptibility to hepatic injury. 
We attempted to follow up on these findings in Mestizo individuals from Mexico City 
with a history of alcohol abuse. In addition to the reported non-synonymous variants rs738409 
and rs6006460, we assayed 15 common tagging SNPs from the PNPLA3 region, 291 SNPs for 
assessing global ancestry7, 16 ancestry-informative markers (AIMs) flanking the PNPLA3 region 
for assessing local ancestry8, and 7 SNPs previously reported to be associated with cirrhosis in 
hepatitis C patients9. We successfully genotyped 305 individuals with apparently normal liver 
function, 434 with intermediate alcoholic liver disease (ALD), and 482 with alcoholic cirrhosis 
(Supplementary Methods online).  
The clinical characteristics of our samples are shown in Table 1. The healthy, alcoholic 
liver disease and cirrhosis diagnosis groups had significant differences in mean age, mean 
alcohol intake and duration, and mean global and local loadings from a principal component 
analysis (PCA) of the genotyping data. Both local and global mean individual Native American 
ancestry were significantly higher among the cirrhosis individuals than the healthy individuals 
(P < 2.2 × 10−16), consistent with the higher prevalence of cirrhosis in Hispanics compared to 
individuals of European or African ancestry3. 
We tested each SNP for association with cirrhosis or ALD using likelihood ratio tests 
from logistic regression, adjusted for age, alcohol intake and duration, an interaction between age 
and duration, and global genetic ancestry estimated using PCA. The association analysis was 
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carried out for three pair-wise combinations of diagnosis results: cirrhosis versus healthy, 
cirrhosis versus ALD, and ALD versus healthy. We also performed tests controlling for local 
ancestry along the 9.4 Mb region flanking rs738409 estimated from PCA using the 16 AIMs. 
SNP rs738409 is strongly associated with alcoholic cirrhosis (Table 2).  
In tests of cirrhosis versus healthy status, rs738409 showed strong association before and 
after controlling for global ancestry, as well as after controlling for local ancestry. Test results 
for cirrhosis versus ALD, and for ALD versus healthy status, suggest that rs738409 has an 
intermediate effect on the ALD phenotype.  We used the Akaike information criterion (AIC) to 
compare four genetic models (2-df general model, and 1-df additive, dominant, and recessive 
risk allele models) in logistic regression adjusting for covariates and the global individual 
ancestry. The most parsimonious model was an additive model for rs738409 [G] (Supplementary 
Table 2 online). Logistic regression analysis suggested that the rs738409 sequence variation 
accounts for 49% of the observed ancestry-related difference in cirrhosis susceptibility (See 
Supplementary Methods). Further tests showed no interactions of rs738409 with other 
covariates, including age, alcohol intake and duration. 
Association test results for the tagging SNPs were generally consistent with their extent 
of linkage disequilibrium (LD) with rs738409 (Supplementary Figure 1 and Table 1 online). SNP 
rs738408 is three base pairs away from rs738409 and is in nearly complete linkage 
disequilibrium (LD) (r2 = 0.99). Association tests for rs738408 gave nearly identical results as 
rs738409. When the SNP rs738409 was treated as causal by including its genotypes as a 
covariate in the regression model, the additional associations in the PNPLA3 region were 
eliminated. All common haplotypes containing the rs738409[G] allele were more common in 
cirrhosis cases than in the healthy group (Supplementary Table 3 online). The rare variant 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
25
4.
2 
: P
os
te
d 
5 
O
ct
 2
00
9
rs6006460[T] reported by Romeo et al.5 is also rare in our Mestizo population (MAF = 0.002) so 
we had no power to detect an effect of this variant. The minor T allele of rs6006460 was 
observed in both the cirrhosis and healthy groups. We did not observe significant associations 
with any of the markers previously reported to be associated with cirrhosis in hepatitis C 
patients9. 
We further tested for an association of rs738409 with prognosis in cirrhosis patients, as 
indicated by Child-Pugh class10. We coded Child-Pugh classes as numeric scores from 1 to 3 in 
order of severity, and fit by linear regression with the same covariates used in the binary 
outcome models and an additive genotype term. The high-risk G allele showed a suggestive 
association with increasing severity (Wald test: one-sided P = 0.05). The frequencies of 
rs738409[G] in patients scored as Child-Pugh class A, B, and C were 0.70, 0.75 and 0.77, 
respectively. 
While the biochemical function of PNPLA3 is unclear, it is primarily expressed in 
adipocytes and may have a role in energy homeostasis11.  Our results suggest that individual 
differences in lipid metabolism can predispose to both alcoholic and non-alcoholic liver injury. 
This further supports a central role for altered lipid metabolism in liver pathogenesis12. Variation 
in PNPLA3 has also been associated with obesity and insulin resistance13. We did not have 
access to metabolic phenotypes in our population, but given these results, it may be useful to 
investigate interactions with body mass, lipid profiles, and insulin sensitivity. 
Our study extends the previously reported associations of rs738409 with subclinical 
nonalcoholic liver disease to clinically relevant endpoints of alcoholic liver disease.  This single 
variant accounts for a substantial share of the increased risk of cirrhosis associated with Hispanic 
ancestry.  Hispanics with hepatitis C are also at substantially elevated risk for hepatic injury 
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compared to other ethnicities14, and it will be important to determine if rs738409 is associated in 
that context as well. The effect size of rs738409 is large for an association with complex disease 
in humans, and may be the largest known genetic modifier for a disease that is a major cause of 
preventable death. For these reasons, this variant may be an attractive target for genetic screening 
to identify individuals at high risk for liver disease for more aggressive interventions. 
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Table 1. Clinical characteristics of the genotyped subjects. 
 
Characteristic Healthy ALD Cirrhosis P value 
Gender: n (%) 0.92 
F 48 (0.16) 67 (0.15) 71 (0.15) 
M 257 (0.84) 367 (0.85) 411 (0.85) 
Intake, gm/week: n (%) 9.4×10−11 
200-500 186 (0.61) 162 (0.37) 179 (0.37) 
500-750 20 (0.07) 46 (0.11) 48 (0.10) 
>750 99 (0.32) 226 (0.52) 255 (0.53) 
Duration, years: mean (sd) 17.5 (9.62) 19.5 (9.89) 26.1 (11.42) <2.2×10−16 
Age, years: mean (sd) 39 (12.7) 41 (12.4) 52 (11.6) <2.2×10−16 
Global PC1 loading: mean (sd) -0.0098 (0.027) -0.00004 (0.024) 0.0058 (0.026) <2.2×10−16 
Local PC1 loading: mean (sd) -0.0094 (0.029) 0.00106 (0.026) 0.0049 (0.027) 5.3×10−12 
 
P values are from F tests for continuous outcomes, and Pearson χ2 tests for categorical outcomes. 
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Table 2. Association test results for rs738409. 
 
Genotype Count Allele Frequency 
Control Case Control Case Allelic Test 
CC CG GG CC CG GG G G OR (95% CI) P 
Cirrhosis vs Healthy 83 198 111 59 264 371 0.54 0.72 2.28 (1.90-2.74) 7.6×10−19 
Cirrhosis vs ALD 91 266 305 59 264 371 0.66 0.72 1.35 (1.14-1.59) 4.2×10−4 
ALD vs Healthy 83 198 111 91 266 305 0.54 0.66 1.69 (1.41-2.03) 0.0012 
 
Logistic Regression Likelihood Ratio Tests 
No Ancestry Correction Global Correction Global and Local Correction 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Cirrhosis vs Healthy 2.25 (1.74-2.90) 1.7×10−10 1.79 (1.37-2.35) 1.9×10−5 1.81 (1.36-2.41) 4.7×10−5 
Cirrhosis vs ALD 1.43 (1.15-1.78) 0.0010 1.33 (1.06-1.66) 0.014 1.45 (1.13-1.84) 0.0028 
ALD vs Healthy 1.45 (1.16-1.80) 8.4×10−4 1.26 (1.00-1.58) 0.051 1.18 (0.92-1.51) 0.19 
 
Genotypes describe the forward strand on NCBI Build 36, and odds ratios are per [G] allele. 
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 Variation in PNPLA3 is associated with outcomes 
in alcoholic liver disease 
 
Chao Tian, Renee P. Stokowski, David Kershenobich, Dennis G. Ballinger, David A. Hinds 
 
Supplementary Methods 
Samples 
Subjects were recruited from clinics in Mexico City based on a history of alcohol abuse. Patients 
with liver disease were enrolled from the liver, gastroenterology, and internal medicine clinics at 
INCMNSZ. Alcoholic controls were enrolled from the Institute of Nutrition at INCMNSZ, as 
well as the Instituto Mexicano de Psiquiatria (IMP) and the Centro de Ayuda al Alcoholico y sus 
Familiares (CAAF). We excluded individuals with other than self-reported Mestizo ancestry. 
Patients with viral hepatitis, or systemic chronic disease (cardiac insufficiency, HIV or 
autoimmune disease, chronic renal insufficiency, or neoplastic disease) were excluded from the 
study. Subjects were assessed for overt liver disease using a combination of clinical and 
biochemical criteria: 
• Clinical criteria: jaundice, spider angiomas, palmar erythema, abnormal collateral 
circulation, ascitis, hepatic encephalopathy, esophageal varices, portal hypertension 
• Biochemical criteria: abnormal aminotransferases, glutamil transpeptidase, alkaline 
phosphatase, decreased serum albumin, increased serum globulin, decreased prothrombin 
Subjects were classified as “healthy” if they had no indicators of liver disease. For patients with 
liver disease, ultrasound or CT screening was used to corroborate diagnoses of cirrhosis. 
Subjects were also assessed for fatty liver and alcoholic hepatitis. Patients with liver disease that 
did not meet the criteria for cirrhosis were classified as “alcoholic liver disease”. Typical alcohol 
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consumption and duration (prior to diagnosis for cirrhosis patients) was determined by interview. 
We excluded individuals reporting fewer than 5 years or less than 200 gm/week of alcohol 
consumption. 
Genotyping 
We genotyped samples on microarrays across 312 autosomal SNPs uniformly distributed across 
the genome for assessment of global population structure. We eliminated microarray scans with 
call rate < 90% and SNPs with call rate < 95%. The microarray data was collected in several 
batches processed at different times. We clustered the combined data together and tested all 
SNPs for batch effects by ANOVA. We identified 2 SNPs with strong batch effects (P < 10−70 
and r2 > 0.2), and an additional 7 SNPs with smaller effects (P < 0.001 and r2 > 0.01). We 
manually inspected cluster plots for these SNPs to confirm that these SNPs did show clustering 
artifacts, and that SNPs with P > 0.001 appeared to be unaffected. We also removed SNPs with 
Hardy Weinberg P < 10−7, based again on manual inspection of cluster diagrams. Across 291 
SNPs passing these filters, the mean call rate was 99.9%. 
Separately, the samples were genotyped across 61 SNPs on the MassArray platform by 
Sequenom. These included the two non-synonymous variants rs738409 and rs6006460 reported 
in Romeo et al.; 17 common tagging SNPs from the region surrounding the PNPLA3 gene; 16 
ancestry informative markers (AIMs) flanking PNPLA3 for assessing local admixture; 7 SNPs 
previously reported to be associated with cirrhosis in patients with chronic hepatitis C; and 18 
quality control (QC) SNPs selected from the microarray panel for verification of sample 
identities. We also included rs738408, a synonymous SNP 3 base pairs away from and in perfect 
LD with rs738409 in the HapMap CEU panel. Where possible, we designed redundant assays in 
opposite orientations, and selected the assay with highest call rate for each SNP. We excluded 
samples with call rate < 80%, SNPs with call rate < 90%, and SNPs with Hardy Weinberg P < 
10−7. We used more generous call rate thresholds for the Sequenom data because missing data 
rates were more broadly distributed than in the microarray data, and these SNPs were considered 
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to be of higher value. There were 4 SNPs (2 tag SNPs, 2 QC SNPs) for which no assays passed 
the quality filters. The remaining 57 SNPs had an average call rate of 98.7%. 
We identified 36 pairs of samples that had nearly identical microarray genotype patterns. 
These cryptic duplicates tended to have correlated ages (r2 = 0.3, P = 0.0002) and diagnoses 
(Fisher’s exact test: P = 0.00003), suggesting that in at least some cases the same individual had 
been recruited twice. An additional 21 samples had low concordance across the 16 SNPs 
successfully genotyped on both platforms. These two groups of samples were excluded from 
analyses. Across the remaining samples, the 16 shared SNPs had an average concordance of 
99.9% across platforms. 
Statistical Analysis 
The significance of the differences in mean sample characteristics such as gender, age, alcoholic 
intake and duration among diagnostic groups were tested using ANOVA. Tests for Hardy-
Weinberg equilibrium were performed for each SNP in each diagnosis group using a likelihood 
ratio test (LRT). All of the tested SNPs were in Hardy-Weinberg equilibrium (P > 0.001) in each 
group.  
Association Tests 
Allelic odds ratios (OR) were estimated from 2×2 contingency tables, and approximate 95% 
confidence intervals (CI) for odds ratios were estimated using Woolf’s method1. The allelic 
association test is the 1 degree of freedom Pearson Chi-square test of the allele frequency 
differences between case and control subjects. A stepwise logistic regression using Akaike 
information criterion (AIC) was also used to define the confounders with disease risk. Age, 
alcohol intake and duration, and an interaction between age and duration were identified as 
significant confounders based on AIC. ORs for cirrhosis risk under an additive genetic model 
were estimated using logistic regression with adjustment for these confounders. The model for 
our primary single SNP association tests can be written as: 
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Logit(π) = β0+ β1*age+ β2*duration + β3*intake+ β4*(age x duration) + β5*genotype  
where π is the likelihood of membership in the case group. The LRT compared models with and 
without the genotype covariate. Detailed results are shown in Supplementary Table 1.  
Estimating Genetic Ancestry 
The genetic diversity due to admixture within the Mestizo population is a known confounder for 
our association tests. To control for spurious association due to differences in ancestry between 
diagnosis groups, we inferred individual global and local ancestry using Principal Components 
Analysis (PCA). Global ancestry was determined for each individual using 291 SNPs distributed 
across the genome. Local ancestry was determined for each individual using 16 AIMs for 
Amerindian and European genetic ancestry flanking the PNPLA3 locus (Supplementary Table 4). 
We incorporated data from additional individuals with self-reported Otomi Indian and European 
ancestry to facilitate interpretation of the PCA results. Individuals with more Native American 
ancestry have larger loadings along the first principal component (Supplementary Figure 2). We 
also applied PCA to just the Mestizo individuals, and found that PC1 had a correlation of 0.9995 
with corresponding results from PCA with the additional samples. PC1 explained substantially 
more genetic variance than the higher order components (Supplementary Figure 3). ANOVA 
tests of the loadings across diagnosis groups show that only PC1 is substantially associated with 
outcomes, for both local and global PCA results. Both local and global ancestry estimation were 
also confirmed by the Bayesian Markov Chain-Monte Carlo (MCMC) method implemented in 
the program STRUCTURE2. STRUCTURE 2.1 was run under the admixture model and k=3 for 
global ancestry estimation, and linkage model and k=2 for local ancestry estimation. We ran the 
MCMC method with burn-in length of 20,000 for 20,000 repetitions. The admixture proportions 
estimated for the most representative ancestry group had a correlation of 0.998 with PC1 of the 
corresponding PCA.  
It is broadly known that the Mestizo population has an admixture of Native American, 
European and African ancestry. We used STRUCTURE to obtain ancestry proportions for our 
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combined Otomi, European, and Mestizo data, together with data from the HapMap YRI panel 
for the same 291 SNPs (Supplementary Figure 4). The results shows that our Mestizo samples 
have about 36.5% (sd 0.214) European, 61.6% (0.22) Native American and 1.9% (0.033) African 
ancestry on average, consistent with a previous report3. The mean individual African ancestry 
estimated using STRUCTURE software is not significantly different among the diagnosis groups 
and is small (< 2%). Thus, we expect to see little confounding in our association studies due to 
African admixture. Association tests controlling for the STRUCTURE results gave nearly 
identical results as controlling for the first PC from global PCA. The first PC has a correlation of 
0.99 with the estimated Native American or European proportion from STRUCTURE. 
Structured Association Tests 
We adjusted for differences in individual global ancestry in association tests by including 
the first PC from global PCA as a covariate in the logistic regression. These tests indicate the 
strength of association attributable to a SNP that is independent of information that SNP might 
indirectly provide about overall ancestry across the genome. To verify that associations could not 
be explained by confounding with local admixture, we also tested SNPs in the PNPLA3 region 
with adjustment for local ancestry by additionally including the first PC from local PCA as a 
covariate. Our models for structured association tests can be written as: 
Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*GPC1+β6*genotype  
Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*GPC1+β6*LPC1+β7*genotype  
where GPC1 is the first PC from global PCA and LPC1 is the first PC from local PCA. The LRT 
compared models with and without the genotype covariate. Detailed results for each SNP are 
shown in Supplementary Table 1.  
To study the genetic risk models for rs738409, we used the AIC to compare four possible 
genetic models: a 2-degree-of-freedom general model, and 1-degree-of-freedom additive, 
dominant, and recessive models. The three possible genotypes [AA,AB,BB] of tested SNPs were 
coded as a three-level factor for the general model, [0,1,2] for the additive model, [0,0,1] for the 
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dominant model, and [0,1,1] for the recessive model. The most parsimonious model was defined 
as the one with the smallest AIC. 
We also assessed the ability of rs738409 to explain ancestry differences in cirrhosis 
susceptibility. Since the rs738409 sequence variation is substantially correlated with global 
ancestry (r = 0.34), we calculated ancestry-adjusted genotypes in which redundancies between 
rs738409 and ancestry were removed, and fit four logistic regression models:  
(1) Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*GPC1+β6*rs738409,  
(2) Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*rs738409 
(3) Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*GPC1+β6*rs738409_adj,  
(4) Logit(π) = β0+β1*age+β2*duration+β3*intake+β4*(age*duration)+β5*rs738409_adj  
Here, rs738409_adj represents residuals from linear regression of rs738409 genotypes against 
global PC1. The proportion of residual deviance explained by global PC1 estimated from models 
(3) and (4) is 6.43%, while the proportion explained by global PC1 estimated from models (1) 
and (2) is 3.28%. Thus, rs738409 accounted for 49% of the observed ancestry-related difference 
in cirrhosis susceptibility. 
Haplotype Analyses 
We used MACH4 version 1.1 to phase genotype data for 18 SNPs in the PNPLA3 region.  We 
performed association tests for each 18-SNP haplotype with observed MAF > 0.01, versus all 
other haplotypes, both using Pearson χ2 tests on 2×2 tables, and logistic regression as in the 
single SNP analyses (Supplementary Table 3). 
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Supplementary Table 1a. Cirrhosis versus Healthy Association Tests. 
Alleles Alt Frequency Allelic Test
rsID Chromosome Position Category LD Ref Alt Control Case P OR (95% CI)
rs4290029 1 222467263 Huang C G 0.69 0.68 8.0E-01 0.97 (0.80–1.18)
rs17740066 3 122582973 Huang G A 0.17 0.23 1.7E-03 1.47 (1.16–1.86)
rs62522600 8 103910885 Huang G A 0.02 0.02 1.7E-01 0.61 (0.33–1.15)
rs4986791 9 119515423 Huang C T 0.02 0.02 6.8E-01 1.23 (0.62–2.45)
rs886277 11 2396343 Huang T C 0.52 0.57 1.5E-02 1.25 (1.05–1.49)
rs2878771 12 48638660 Huang G C 0.12 0.08 2.8E-03 0.64 (0.48–0.85)
rs2290351 15 88175785 Huang G A 0.37 0.42 1.4E-02 1.26 (1.05–1.51)
rs9614194 22 42636398 LDtag 0.027 G A 0.04 0.01 2.0E-04 0.34 (0.20–0.61)
rs5764023 22 42636551 LDtag 0.031 C T 0.20 0.25 9.2E-03 1.34 (1.08–1.67)
rs4823168 22 42638868 LDtag 0.000 C T 0.27 0.24 1.3E-01 0.85 (0.70–1.04)
rs929090 22 42645182 LDtag 0.010 A G 0.55 0.56 7.0E-01 1.04 (0.86–1.26)
rs4823104 22 42652482 LDtag 0.021 A G 0.05 0.03 1.5E-01 0.70 (0.45–1.09)
rs2076213 22 42654255 LDtag 0.070 T G 0.19 0.26 2.9E-04 1.50 (1.21–1.86)
rs2076212 22 42654303 LDtag 0.037 G T 0.10 0.07 7.7E-03 0.64 (0.47–0.88)
rs738407 22 42655288 LDtag 0.531 T C 0.60 0.75 1.6E-12 2.03 (1.67–2.47)
rs139051 22 42656009 LDtag 0.473 A G 0.38 0.23 1.3E-13 0.49 (0.40–0.59)
rs738409 22 42656060 Romeo 1.000 C G 0.54 0.72 7.7E-19 2.28 (1.90–2.74)
rs738408 22 42656063 Romeo 0.988 C T 0.54 0.72 2.3E-17 2.21 (1.84–2.65)
rs1883350 22 42659376 LDtag 0.776 T C 0.56 0.73 4.7E-15 2.11 (1.75–2.54)
rs4823173 22 42660063 LDtag 0.833 G A 0.49 0.69 5.7E-19 2.28 (1.90–2.73)
rs2076208 22 42662393 LDtag 0.273 G C 0.84 0.88 3.2E-02 1.33 (1.03–1.71)
rs2294916 22 42672255 LDtag 0.791 T G 0.49 0.67 1.4E-16 2.14 (1.79–2.57)
rs2294918 22 42673449 LDtag 0.352 A G 0.76 0.87 2.0E-09 2.02 (1.60–2.54)
rs6006460 22 42673507 Romeo 0.008 G T 0.00 0.00 5.1E-01 0.37 (0.06–2.24)
rs2294919 22 42673658 LDtag 0.279 C T 0.17 0.13 9.5E-03 0.72 (0.56–0.92)
 
Logistic Regression Likelihood Ratio Tests
No Ancestry Correction Global Correction Global & Local Correction Condition on rs738409
rsID P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs4290029 4.5E-01 1.11 (0.85–1.45) 7.0E-02 1.29 (0.98–1.71)
rs17740066 8.8E-03 1.49 (1.10–2.02) 6.3E-02 1.35 (0.98–1.86)
rs62522600 5.7E-02 0.43 (0.18–1.03) 3.3E-01 0.64 (0.26–1.57)
rs4986791 4.2E-01 0.70 (0.30–1.65) 9.0E-01 0.94 (0.38–2.32)
rs886277 7.2E-02 1.25 (0.98–1.59) 3.5E-01 1.13 (0.88–1.45)
rs2878771 1.3E-03 0.52 (0.35–0.78) 3.5E-02 0.64 (0.43–0.97)
rs2290351 7.1E-02 1.25 (0.98–1.59) 7.1E-01 1.05 (0.81–1.35)
rs9614194 6.6E-04 0.29 (0.14–0.60) 5.9E-03 0.36 (0.17–0.75) 1.7E-02 0.41 (0.20–0.86) 7.0E-02 0.49 (0.23–1.07)
rs5764023 2.9E-01 1.17 (0.87–1.57) 8.8E-01 1.02 (0.75–1.39) 9.4E-01 1.01 (0.75–1.37) 5.6E-01 0.91 (0.66–1.25)
rs4823168 5.7E-01 0.92 (0.70–1.21) 9.0E-01 0.98 (0.74–1.30) 9.0E-01 1.02 (0.77–1.35) 9.6E-01 1.01 (0.76–1.34)
rs929090 6.8E-01 1.05 (0.82–1.35) 8.3E-01 0.97 (0.75–1.26) 7.6E-01 0.96 (0.74–1.24) 6.1E-01 0.93 (0.72–1.22)
rs4823104 1.9E-01 0.67 (0.38–1.20) 9.3E-01 0.97 (0.54–1.76) 8.8E-01 0.95 (0.52–1.75) 9.6E-01 1.02 (0.55–1.88)
rs2076213 8.4E-02 1.28 (0.96–1.71) 6.9E-01 1.06 (0.79–1.43) 8.6E-01 1.03 (0.76–1.39) 5.9E-01 0.92 (0.67–1.25)
rs2076212 1.2E-02 0.59 (0.40–0.89) 4.6E-02 0.65 (0.43–0.99) 3.6E-02 0.64 (0.42–0.97) 2.3E-01 0.77 (0.50–1.18)
rs738407 1.8E-06 1.87 (1.44–2.42) 1.1E-02 1.44 (1.09–1.90) 3.2E-02 1.39 (1.03–1.87) 5.3E-01 0.88 (0.60–1.30)
rs139051 2.0E-06 0.53 (0.41–0.69) 8.6E-03 0.69 (0.52–0.91) 4.1E-02 0.73 (0.53–0.99) 9.3E-01 1.02 (0.70–1.47)
rs738409 1.7E-10 2.25 (1.74–2.90) 1.9E-05 1.79 (1.37–2.35) 4.7E-05 1.81 (1.36–2.41)   
rs738408 3.0E-10 2.25 (1.74–2.91) 2.8E-05 1.79 (1.36–2.35) 5.5E-05 1.81 (1.35–2.42) 9.9E-01 1.01 (0.11–9.15)
rs1883350 6.4E-07 1.83 (1.44–2.32) 4.2E-03 1.45 (1.13–1.88) 1.2E-02 1.42 (1.08–1.86) 2.0E-01 0.71 (0.42–1.20)
rs4823173 9.9E-10 2.10 (1.64–2.67) 1.8E-04 1.65 (1.27–2.14) 4.9E-04 1.67 (1.25–2.22) 1.0E+00 1.00 (0.55–1.82)
rs2076208 1.2E-01 1.31 (0.93–1.84) 4.0E-01 1.16 (0.82–1.65) 2.8E-01 1.21 (0.86–1.72) 1.4E-01 0.73 (0.49–1.11)
rs2294916 8.2E-08 1.91 (1.50–2.43) 2.0E-03 1.50 (1.16–1.95) 6.9E-03 1.48 (1.11–1.96) 3.5E-01 0.78 (0.46–1.32)
rs2294918 1.4E-04 1.87 (1.35–2.58) 2.9E-02 1.46 (1.04–2.04) 1.1E-01 1.34 (0.94–1.91) 7.9E-01 0.95 (0.63–1.43)
rs6006460 5.8E-01 0.49 (0.04–5.52) 6.8E-01 0.59 (0.05–6.72) 9.4E-01 1.10 (0.09–13.3) 9.1E-01 0.86 (0.07–10.2)
rs2294919 1.9E-02 0.67 (0.48–0.94) 1.3E-01 0.77 (0.54–1.08) 6.9E-02 0.73 (0.52–1.02) 4.0E-01 1.19 (0.80–1.77)
 
Chromosomal positions and alleles are given for the forward strand of NCBI Build 36. ‘LD’ indicates r2 
with rs738409. Odds ratios are specified per alternate allele. 
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Supplementary Table 1b. Cirrhosis versus ALD Association Tests. 
Alleles Alt Frequency Allelic Test
rsID Chromosome Position Category LD Ref Alt Control Case P OR (95% CI)
rs4290029 1 222467263 Huang C G 0.69 0.68 3.6E-01 1.08 (0.92–1.28)
rs17740066 3 122582973 Huang G A 0.17 0.23 2.9E-02 1.25 (1.03–1.53)
rs62522600 8 103910885 Huang G A 0.02 0.02 6.3E-01 0.83 (0.46–1.49)
rs4986791 9 119515423 Huang C T 0.02 0.02 8.5E-01 0.91 (0.53–1.57)
rs886277 11 2396343 Huang T C 0.52 0.57 4.9E-01 0.94 (0.81–1.10)
rs2878771 12 48638660 Huang G C 0.12 0.08 3.1E-01 0.86 (0.66–1.13)
rs2290351 15 88175785 Huang G A 0.37 0.42 8.7E-01 0.98 (0.85–1.15)
rs9614194 22 42636398 LDtag 0.027 G A 0.04 0.01 7.5E-01 0.86 (0.47–1.59)
rs5764023 22 42636551 LDtag 0.031 C T 0.20 0.25 3.2E-01 1.10 (0.92–1.32)
rs4823168 22 42638868 LDtag 0.000 C T 0.27 0.24 5.3E-01 1.06 (0.89–1.27)
rs929090 22 42645182 LDtag 0.010 A G 0.55 0.56 5.8E-01 1.05 (0.89–1.23)
rs4823104 22 42652482 LDtag 0.021 A G 0.05 0.03 8.2E-01 0.93 (0.62–1.40)
rs2076213 22 42654255 LDtag 0.070 T G 0.19 0.26 2.9E-02 1.22 (1.02–1.46)
rs2076212 22 42654303 LDtag 0.037 G T 0.10 0.07 7.8E-01 0.95 (0.70–1.28)
rs738407 22 42655288 LDtag 0.531 T C 0.60 0.75 4.0E-02 1.21 (1.01–1.45)
rs139051 22 42656009 LDtag 0.473 A G 0.38 0.23 1.8E-01 0.88 (0.74–1.05)
rs738409 22 42656060 Romeo 1.000 C G 0.54 0.72 4.2E-04 1.35 (1.14–1.59)
rs738408 22 42656063 Romeo 0.988 C T 0.54 0.72 1.3E-03 1.31 (1.11–1.55)
rs1883350 22 42659376 LDtag 0.776 T C 0.56 0.73 3.3E-03 1.29 (1.09–1.52)
rs4823173 22 42660063 LDtag 0.833 G A 0.49 0.69 2.8E-03 1.28 (1.09–1.51)
rs2076208 22 42662393 LDtag 0.273 G C 0.84 0.88 1.5E-03 1.43 (1.15–1.77)
rs2294916 22 42672255 LDtag 0.791 T G 0.49 0.67 6.5E-03 1.25 (1.07–1.47)
rs2294918 22 42673449 LDtag 0.352 A G 0.76 0.87 7.1E-01 1.05 (0.84–1.31)
rs6006460 22 42673507 Romeo 0.008 G T 0.00 0.00 5.8E-02 0.21 (0.05–0.97)
rs2294919 22 42673658 LDtag 0.279 C T 0.17 0.13 1.1E-03 0.70 (0.57–0.86)
 
Logistic Regression Likelihood Ratio Tests
No Ancestry Correction Global Correction Global & Local Correction Condition on rs738409
rsID P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs4290029 9.7E-01 1.00 (0.80–1.24) 6.9E-01 1.05 (0.84–1.31)
rs17740066 7.7E-02 1.26 (0.97–1.64) 1.5E-01 1.21 (0.93–1.57)
rs62522600 8.1E-01 0.90 (0.39–2.10) 9.3E-01 1.04 (0.44–2.44)
rs4986791 5.5E-01 0.80 (0.39–1.64) 6.8E-01 0.86 (0.42–1.76)
rs886277 3.5E-01 0.91 (0.74–1.11) 2.0E-01 0.87 (0.71–1.07)
rs2878771 4.7E-02 0.70 (0.49–1.00) 1.2E-01 0.75 (0.52–1.08)
rs2290351 5.8E-01 1.06 (0.86–1.30) 9.6E-01 0.99 (0.80–1.23)
rs9614194 6.9E-01 0.86 (0.41–1.82) 9.5E-01 0.98 (0.45–2.10) 9.1E-01 0.96 (0.44–2.06) 8.2E-01 1.09 (0.51–2.35)
rs5764023 2.4E-01 1.16 (0.91–1.48) 3.8E-01 1.12 (0.87–1.43) 3.0E-01 1.14 (0.89–1.46) 6.1E-01 1.07 (0.83–1.37)
rs4823168 5.6E-01 1.07 (0.84–1.36) 4.1E-01 1.11 (0.87–1.41) 4.5E-01 1.10 (0.86–1.40) 4.2E-01 1.10 (0.87–1.41)
rs929090 4.1E-01 1.09 (0.89–1.34) 5.2E-01 1.07 (0.87–1.32) 4.6E-01 1.08 (0.88–1.33) 5.8E-01 1.06 (0.86–1.31)
rs4823104 5.0E-01 0.84 (0.51–1.39) 9.4E-01 0.98 (0.59–1.64) 7.7E-01 0.92 (0.54–1.57) 9.0E-01 1.04 (0.62–1.74)
rs2076213 7.3E-02 1.25 (0.98–1.60) 2.4E-01 1.17 (0.90–1.50) 1.3E-01 1.22 (0.94–1.57) 5.0E-01 1.09 (0.84–1.42)
rs2076212 7.5E-01 1.07 (0.72–1.59) 5.6E-01 1.13 (0.75–1.68) 6.3E-01 1.10 (0.74–1.65) 3.0E-01 1.24 (0.82–1.87)
rs738407 3.6E-02 1.28 (1.02–1.63) 2.1E-01 1.17 (0.91–1.50) 8.1E-02 1.28 (0.97–1.68) 5.2E-01 0.89 (0.63–1.26)
rs139051 2.8E-02 0.77 (0.61–0.97) 2.2E-01 0.85 (0.67–1.10) 8.5E-02 0.79 (0.60–1.03) 6.8E-01 1.07 (0.77–1.48)
rs738409 1.0E-03 1.43 (1.15–1.78) 1.4E-02 1.33 (1.06–1.66) 2.8E-03 1.45 (1.13–1.84)    
rs738408 1.8E-03 1.41 (1.13–1.75) 2.1E-02 1.30 (1.04–1.63) 4.8E-03 1.42 (1.11–1.81) 3.1E-01 0.36 (0.04–3.18)
rs1883350 1.5E-02 1.30 (1.05–1.61) 1.3E-01 1.19 (0.95–1.48) 5.0E-02 1.27 (1.00–1.61) 3.4E-01 0.78 (0.47–1.30)
rs4823173 4.3E-03 1.35 (1.10–1.67) 5.9E-02 1.24 (0.99–1.55) 1.0E-02 1.38 (1.08–1.77) 6.0E-01 0.87 (0.51–1.47)
rs2076208 3.2E-02 1.36 (1.03–1.81) 6.3E-02 1.31 (0.98–1.75) 4.4E-02 1.34 (1.01–1.78) 4.3E-01 1.15 (0.81–1.65)
rs2294916 1.1E-02 1.31 (1.06–1.61) 1.1E-01 1.20 (0.96–1.49) 2.6E-02 1.32 (1.03–1.68) 3.6E-01 0.81 (0.51–1.28)
rs2294918 2.1E-01 1.22 (0.90–1.65) 5.7E-01 1.10 (0.80–1.50) 4.1E-01 1.15 (0.83–1.59) 3.2E-01 0.83 (0.56–1.21)
rs6006460 7.4E-02 0.24 (0.04–1.30) 1.4E-01 0.30 (0.06–1.63) 1.1E-01 0.28 (0.05–1.52) 2.3E-01 0.37 (0.07–2.03)
rs2294919 1.9E-02 0.71 (0.54–0.95) 4.3E-02 0.75 (0.56–0.99) 2.9E-02 0.73 (0.55–0.97) 4.5E-01 0.87 (0.61–1.24)
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Supplementary Table 1c. ALD versus Healthy Association Tests. 
Alleles Alt Frequency Allelic Test
rsID Chromosome Position Category LD Ref Alt Control Case P OR (95% CI)
rs4290029 1 222467263 Huang C G 0.69 0.68 2.9E-01 0.90 (0.74–1.09)
rs17740066 3 122582973 Huang G A 0.17 0.23 2.2E-01 1.17 (0.92–1.49)
rs62522600 8 103910885 Huang G A 0.02 0.02 4.2E-01 0.74 (0.40–1.36)
rs4986791 9 119515423 Huang C T 0.02 0.02 5.0E-01 1.34 (0.68–2.67)
rs886277 11 2396343 Huang T C 0.52 0.57 2.4E-03 1.32 (1.11–1.58)
rs2878771 12 48638660 Huang G C 0.12 0.08 4.6E-02 0.74 (0.56–0.98)
rs2290351 15 88175785 Huang G A 0.37 0.42 9.4E-03 1.28 (1.06–1.53)
rs9614194 22 42636398 LDtag 0.027 G A 0.04 0.01 1.2E-03 0.40 (0.23–0.69)
rs5764023 22 42636551 LDtag 0.031 C T 0.20 0.25 8.7E-02 1.22 (0.98–1.52)
rs4823168 22 42638868 LDtag 0.000 C T 0.27 0.24 3.8E-02 0.80 (0.65–0.98)
rs929090 22 42645182 LDtag 0.010 A G 0.55 0.56 9.9E-01 0.99 (0.82–1.20)
rs4823104 22 42652482 LDtag 0.021 A G 0.05 0.03 2.5E-01 0.75 (0.49–1.17)
rs2076213 22 42654255 LDtag 0.070 T G 0.19 0.26 8.3E-02 1.22 (0.98–1.53)
rs2076212 22 42654303 LDtag 0.037 G T 0.10 0.07 2.1E-02 0.68 (0.49–0.93)
rs738407 22 42655288 LDtag 0.531 T C 0.60 0.75 2.5E-07 1.67 (1.38–2.03)
rs139051 22 42656009 LDtag 0.473 A G 0.38 0.23 9.2E-10 0.55 (0.46–0.67)
rs738409 22 42656060 Romeo 1.000 C G 0.54 0.72 1.2E-08 1.69 (1.41–2.03)
rs738408 22 42656063 Romeo 0.988 C T 0.54 0.72 2.4E-08 1.68 (1.40–2.02)
rs1883350 22 42659376 LDtag 0.776 T C 0.56 0.73 1.9E-07 1.64 (1.36–1.97)
rs4823173 22 42660063 LDtag 0.833 G A 0.49 0.69 5.4E-10 1.78 (1.48–2.13)
rs2076208 22 42662393 LDtag 0.273 G C 0.84 0.88 6.0E-01 0.93 (0.73–1.19)
rs2294916 22 42672255 LDtag 0.791 T G 0.49 0.67 6.0E-09 1.71 (1.43–2.05)
rs2294918 22 42673449 LDtag 0.352 A G 0.76 0.87 2.9E-08 1.92 (1.53–2.42)
rs6006460 22 42673507 Romeo 0.008 G T 0.00 0.00 5.6E-01 1.78 (0.48–6.60)
rs2294919 22 42673658 LDtag 0.279 C T 0.17 0.13 8.6E-01 1.03 (0.81–1.30)
 
Logistic Regression Likelihood Ratio Tests
No Ancestry Correction Global Correction Global & Local Correction Condition on rs738409
rsID P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs4290029 9.6E-01 0.99 (0.79–1.25) 3.9E-01 1.11 (0.87–1.41)
rs17740066 1.0E-01 1.27 (0.95–1.70) 2.9E-01 1.17 (0.87–1.57)
rs62522600 2.8E-01 0.68 (0.33–1.38) 5.1E-01 0.79 (0.38–1.61)
rs4986791 7.4E-01 1.14 (0.52–2.48) 4.7E-01 1.33 (0.60–2.94)
rs886277 3.7E-02 1.26 (1.01–1.56) 1.3E-01 1.18 (0.95–1.47)
rs2878771 3.3E-01 0.85 (0.61–1.18) 9.7E-01 1.01 (0.71–1.42)
rs2290351 7.2E-02 1.23 (0.98–1.53) 4.1E-01 1.10 (0.87–1.39)
rs9614194 4.5E-03 0.41 (0.22–0.77) 4.0E-02 0.52 (0.27–0.98) 6.8E-02 0.56 (0.29–1.06) 1.0E-01 0.59 (0.31–1.12)
rs5764023 7.3E-01 1.05 (0.80–1.38) 9.9E-01 1.00 (0.76–1.32) 9.3E-01 0.99 (0.75–1.30) 8.9E-01 0.98 (0.74–1.29)
rs4823168 2.7E-01 0.87 (0.68–1.11) 3.5E-01 0.89 (0.69–1.14) 5.8E-01 0.93 (0.72–1.20) 3.4E-01 0.88 (0.69–1.14)
rs929090 8.6E-01 0.98 (0.78–1.23) 5.1E-01 0.92 (0.73–1.17) 5.5E-01 0.93 (0.74–1.17) 4.7E-01 0.92 (0.72–1.16)
rs4823104 4.4E-01 0.82 (0.50–1.35) 9.9E-01 1.00 (0.60–1.65) 7.7E-01 1.08 (0.65–1.80) 8.8E-01 1.04 (0.62–1.73)
rs2076213 9.1E-01 1.02 (0.78–1.33) 4.7E-01 0.90 (0.68–1.19) 4.6E-01 0.90 (0.68–1.19) 2.7E-01 0.85 (0.64–1.13)
rs2076212 6.8E-02 0.71 (0.49–1.03) 2.1E-01 0.78 (0.53–1.14) 2.1E-01 0.78 (0.54–1.15) 3.3E-01 0.83 (0.56–1.22)
rs738407 1.9E-03 1.45 (1.15–1.84) 1.5E-01 1.20 (0.94–1.55) 3.4E-01 1.14 (0.87–1.49) 9.8E-01 1.00 (0.71–1.39)
rs139051 1.4E-03 0.69 (0.55–0.87) 7.4E-02 0.80 (0.63–1.02) 3.2E-01 0.87 (0.67–1.14) 4.3E-01 0.88 (0.63–1.22)
rs738409 8.4E-04 1.45 (1.16–1.80) 5.1E-02 1.26 (1.00–1.58) 1.9E-01 1.18 (0.92–1.51)    
rs738408 1.4E-03 1.43 (1.15–1.78) 7.7E-02 1.23 (0.98–1.56) 2.7E-01 1.15 (0.90–1.48) 7.1E-01 1.75 (0.10–31.2)
rs1883350 3.7E-03 1.37 (1.11–1.70) 1.3E-01 1.19 (0.95–1.49) 3.1E-01 1.13 (0.89–1.44) 7.0E-01 0.92 (0.59–1.42)
rs4823173 3.6E-04 1.47 (1.19–1.82) 5.0E-02 1.25 (1.00–1.57) 2.0E-01 1.18 (0.92–1.52) 6.1E-01 1.15 (0.67–1.96)
rs2076208 6.9E-01 0.94 (0.71–1.26) 5.7E-01 0.92 (0.69–1.23) 6.3E-01 0.93 (0.70–1.25) 5.4E-02 0.72 (0.51–1.01)
rs2294916 1.1E-03 1.42 (1.15–1.76) 9.2E-02 1.22 (0.97–1.53) 3.3E-01 1.13 (0.88–1.46) 9.8E-01 1.01 (0.61–1.67)
rs2294918 1.3E-03 1.59 (1.20–2.11) 4.3E-02 1.35 (1.01–1.82) 1.4E-01 1.26 (0.93–1.72) 1.8E-01 1.26 (0.89–1.78)
rs6006460 2.1E-01 3.31 (0.39–28.0) 9.2E-02 4.84 (0.56–41.7) 7.9E-02 5.08 (0.60–43.2) 6.3E-02 5.71 (0.65–50.0)
rs2294919 8.0E-01 1.04 (0.78–1.37) 5.9E-01 1.08 (0.81–1.44) 6.1E-01 1.08 (0.81–1.43) 5.5E-02 1.39 (0.99–1.94)
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Supplementary Table 2. Akaike information criterion (AIC) for rs738409[G] model selection. 
Model Cirrhosis vs. Healthy Cirrhosis vs. ALD
General 2-df 772.9 1091.6 
Additive 770.9 1089.7 
Dominant 779.9 1093.3 
Recessive 774.8 1090.4 
 
Supplementary Table 3. Haplotype association tests, for cirrhosis vs healthy status. 
 Pearson Logistic Regression 
Frequency  χ2 test Corrected for Global PC1 
Haplotype case control  P OR 95% CI P 
GCCAATGCAGTCACGGGC 0.2158 0.1672  0.0217 1.34 (1.01,1.80) 0.0439 
GTCGAGGCAGTCACGGGC 0.1546 0.1115  0.0192 1.57 (1.09,2.27) 0.0133 
GCTGATGCAGTCACGGGC 0.1369 0.0934  0.0122 1.77 (1.19,2.63) 0.0038 
GCCAATGTGCCTGCTAGC 0.0664 0.1049  0.0085 0.55 (0.36,0.83) 0.0055 
GTCGATGCAGTCACGGGC 0.0446 0.0311  0.2285 0.92 (0.50,1.67) 0.7828 
GCCAAGGCAGTCACGGGC 0.0353 0.0295  0.6324 1.15 (0.61,2.17) 0.6662 
GCCAATGTACCTGGTGGT 0.0332 0.0344  0.9908 1.20 (0.61,2.38) 0.5991 
GCCGATGCAGTCACGGGC 0.0290 0.0279  0.9850 1.12 (0.54,2.30) 0.7576 
GCTGGTGTGCCTGCTAGC 0.0145 0.0131  0.9908 1.11 (0.41,3.03) 0.8327 
GCCGATTTACCTGGTGGT 0.0124 0.0246  0.1078 0.55 (0.24,1.22) 0.1447 
GCTGATGTGCCTGCTAGC 0.0114 0.0311  0.0093 0.45 (0.19,1.08) 0.0658 
 
Supplementary Table 4. Markers used for local ancestry assessment.  
rsID Chromosome Position 
rs739363 22 38090829 
rs12484697 22 39066418 
rs1984584 22 40014372 
rs132793 22 40393627 
rs7364180 22 40548802 
rs2142695 22 40911192 
rs2076158 22 41619682 
rs733181 22 41984410 
rs873724 22 43487691 
rs961500 22 43717774 
rs2283663 22 44320140 
rs5767329 22 45473836 
rs713999 22 46210776 
rs5767830 22 46381466 
rs5768714 22 47309834 
rs132220 22 47463076 
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Supplementary Figure 1. Linkage disequilibrium of genotyped SNPs in the PNPLA3 region, 
generated by Haploview5. Scores represent r2 observed in our sample set. 
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Supplementary Figure 2. Distribution of (a) global and (b) local genetic ancestry along PC1 
and PC2 estimated from PCA, colored by self-reported ancestry. In both analyses, PC1 measures 
Native American versus European ancestry; PC2 and higher components were not strongly 
correlated with self-reported ancestry. 
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Supplementary Figure 3. Variance components from (a) global and (b) local PCA. The first 
principal components account for substantially more variance than the higher order components. 
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Supplementary Figure 4. Global admixture proportions estimated from STRUCTURE. The 
individuals are sorted according to their global PC1 loadings, where larger loadings indicate 
higher Native American admixture proportions. 
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